Company Overview and News
After the September disclosure of the largest consumer information data breach in US history and the significant price decline in its stock, Equifax (EFX) offered investors a high risk-high reward proposition. Equifax was an excellent wide moat business available cheaply because of significant legal and regulatory risks.
Investor reaction to Equifax Inc.’s (EFX - Free Report) latest quarterly results were mixed as evident from yesterday’s late-hour trade. Following the company’s third-quarter 2017 results, the stock fell approximately 2.5%, then recovered and went up to nearly 1%. Finally, at the close of after-hour trading, it was down less than 1%.
Equifax Inc. (EFX - Free Report) recently completed the acquisition of ID Watchdog in an all-cash deal. The company had entered into a definitive agreement to acquire ID Watchdog on Jun 16, 2017. Per the agreement, Equifax will pay approximately $63 million in cash, which translates to nearly 40 cents per share, to acquire all outstanding shares of ID Watchdog. The buyout is aimed to provide a boost to Equifax’s capabilities to serve customers better.
Equifax Inc. (EFX - Free Report) reported mixed results for second-quarter 2017. The company’s adjusted earnings (excluding amortization expenses, Veda Group acquisition-related charges and other one-time items) per share from continuing operations of $1.60 surpassed the Zacks Consensus Estimate of $1.57 and also jumped 11.9% year over year.
In a recent development, Equifax Inc. (EFX - Free Report) entered into a definitive agreement to acquire ID Watchdog. The acquisition, which is anticipated to close in third-quarter 2017, is aimed at boosting Equifax’s capabilities to serve its customers better.
Leading data management company Equifax Inc. (EFX - Free Report) recently expanded its strategic alliance with BizEquity, a global leader of business valuation knowledge and big data. The agreement aims at enhancing Equifax’s capabilities to serve its customers better.
Keeping its earnings streak alive for the ninth time in a row, Equifax Inc. (EFX - Free Report) reported better-than-expected results for first-quarter 2017. The company’s adjusted earnings (excluding amortization expenses, Veda Group acquisition-related charges and other one-time items) per share from continuing operations of $1.44 surpassed the Zacks Consensus Estimate of $1.41 and also jumped 16.
Keeping its earnings streak alive for the eighth time in a row, Equifax Inc. (EFX - Free Report) reported better-than-expected results for the fourth quarter of 2016. The company’s adjusted earnings (excluding amortization expenses, Veda Group acquisition-related charges and other one-time items) per share from continuing operations of $1.42 surpassed the Zacks Consensus Estimate of $1.38 and surged 24.
Shares of Equifax Inc. (EFX - Analyst Report) have been gaining solid momentum of late. One of the major reasons behind this could be the company’s better-than-expected fourth-quarter 2015 results that also improved year over year. Also, an encouraging first-quarter and full-year 2016 outlook drove the shares higher.
Shares of Equifax Inc. (EFX - Analyst Report) hit a new 52-week high of $114.67 on Mar 31. The company has been gaining significantly supported by the ongoing growth initiatives, product innovation, shareholder-friendly moves and impressive quarterly results.
2018-04-18 - Asif
History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...
2018-04-16 - Asif
Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...
2018-04-16 - Asif
Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...
2018-04-15 - Asif
Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...
2018-04-12 - Asif
Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...